These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11893342)

  • 1. Potential cost savings of erythropoietin administration in end-stage renal disease.
    Hynes DM; Stroupe KT; Greer JW; Reda DJ; Frankenfield DL; Kaufman JS; Henderson WG; Owen WF; Rocco MV; Wish JB; Kang J; Feussner JR
    Am J Med; 2002 Feb; 112(3):169-75. PubMed ID: 11893342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing epoetin therapy in end-stage renal disease: the case for subcutaneous administration.
    Besarab A
    Am J Kidney Dis; 1993 Aug; 22(2 Suppl 1):13-22. PubMed ID: 8352267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous erythropoietin therapy: efficacy and economic implications.
    Kaufman JS
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S147-51. PubMed ID: 9892382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.
    Piccoli A; Puggia RM; Fusaro M; Favaro E; Pillon L
    Pharmacoeconomics; 1995 May; 7(5):444-56. PubMed ID: 10155331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of an intravenous to subcutaneous epoetin α conversion.
    Wazny LD; Raymond CB; Sood AR; Eng A; Verrelli M
    Am J Nephrol; 2013; 38(6):496-500. PubMed ID: 24334854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis.
    Goodkin DA; Gimenez LF; Graber SE; Van Stone JC; Egrie JC; Okamoto DM
    Clin Nephrol; 1999 Jun; 51(6):367-72. PubMed ID: 10404697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rationale for an individualized administration frequency of epoetin beta: a clinical perspective.
    Weiss L
    Nephrol Dial Transplant; 2002; 17 Suppl 6():8-12. PubMed ID: 12091595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.
    Harris DC
    Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.
    Thamer M; Zhang Y; Kaufman J; Stefanik K; Cotter DJ
    Am J Kidney Dis; 2006 Jul; 48(1):77-87. PubMed ID: 16797389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of once-weekly epoetin alfa.
    Barre P; Reichel H; Suranyi MG; Barth C
    Clin Nephrol; 2004 Dec; 62(6):440-8. PubMed ID: 15630903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
    Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
    Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.